ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI To Fund 840 Competing Grants In FY 1991; No Downward Negotiations, But Careful Review

December 7, 1990

Bristol Stock Drops Amid New Setbacks, Deepening Firm’s Decline In Oncology

April 5, 2002

New Saccharin Studies Convince FDA It A Carcinogen

July 15, 1977

NCAB Committee To Propose Event Marking Cancer Act

August 2, 1991

FDA Relies on Importation, Fast Approval, and Early Reporting to Combat Drug Shortages

February 24, 2012

Scientific Opportunity Should Guide Fund Allocation, House Says

August 4, 1995